Monthly Anti-VEGF Dosing Associated With Lowest Risk Of Macular Hemorrhage
Patients with neovascular age-related macular degeneration being treated with monthly dosing of intravitreal anti-VEGF therapy have the lowest rate of macular hemorrhage compared with patients treated with sham or alternative therapy and have lower rates than patients treated with quarterly dosing schemes, according to a study.